Imaging Outcomes for Phase 2 Trials Targeting Compartmentalized Inflammation

Overview

Journal Mult Scler

Publisher Sage Publications

Specialty Neurology

Date 2024 Dec 11

PMID 39658905

Authors

Maria I Gaitan

Rocio V Marquez

Jeremias Ayerbe

Daniel S Reich

Affiliations

Soon will be listed here.

Abstract

This comprehensive review aims to explore imaging outcome measures targeting compartmentalized inflammation in Phase 2 clinical trials for multiple sclerosis (MS). The traditional primary imaging outcomes used in Phase 2 MS trials, new or enhancing white matter lesions on MRI, target the effects of peripheral inflammation, but the widespread inflammation behind a mostly closed blood-brain barrier is not captured. This review discusses several emerging imaging technologies that could be used as surrogate markers of compartmentalized inflammation, targeting chronic active lesions, meningeal inflammation, and innate immune activation within the normal-appearing white matter and gray matter. The integration of specific imaging outcomes into Phase 2 trials can provide a more accurate assessment of treatment efficacy, ultimately contributing to the development of more effective therapies for MS.

References

Clarke M, Pareto D, Pessini-Ferreira L, Arrambide G, Alberich M, Crescenzo F . Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. AJNR Am J Neuroradiol. 2020; 41(6):1001-1008. PMC: 7342768. DOI: 10.3174/ajnr.A6547. View

Kee R, Naughton M, McDonnell G, Howell O, Fitzgerald D . A Review of Compartmentalised Inflammation and Tertiary Lymphoid Structures in the Pathophysiology of Multiple Sclerosis. Biomedicines. 2022; 10(10). PMC: 9599335. DOI: 10.3390/biomedicines10102604. View

Treaba C, Granberg T, Sormani M, Herranz E, Ouellette R, Louapre C . Longitudinal Characterization of Cortical Lesion Development and Evolution in Multiple Sclerosis with 7.0-T MRI. Radiology. 2019; 291(3):740-749. PMC: 6543899. DOI: 10.1148/radiol.2019181719. View

Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007; 130(Pt 4):1089-104. DOI: 10.1093/brain/awm038. View

Lublin F, Reingold S, Cohen J, Cutter G, Soelberg Sorensen P, Thompson A . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 83(3):278-86. PMC: 4117366. DOI: 10.1212/WNL.0000000000000560. View

Prineas J, Kwon E, Cho E, Sharer L, Barnett M, Oleszak E . Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001; 50(5):646-57. DOI: 10.1002/ana.1255. View

Stuber C, Pitt D, Wang Y . Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping. Int J Mol Sci. 2016; 17(1). PMC: 4730342. DOI: 10.3390/ijms17010100. View

Tsouki F, Williams A . Multifaceted involvement of microglia in gray matter pathology in multiple sclerosis. Stem Cells. 2021; 39(8):993-1007. DOI: 10.1002/stem.3374. View

Bagnato F, Sati P, Hemond C, Elliott C, Gauthier S, Harrison D . Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain. 2024; 147(9):2913-2933. PMC: 11370808. DOI: 10.1093/brain/awae013. View

10.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S . Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1):43. DOI: 10.1038/s41572-018-0041-4. View

11.

Beck E, Gai N, Filippini S, Maranzano J, Nair G, Reich D . Inversion Recovery Susceptibility Weighted Imaging With Enhanced T2 Weighting at 3 T Improves Visualization of Subpial Cortical Multiple Sclerosis Lesions. Invest Radiol. 2020; 55(11):727-735. PMC: 7541598. DOI: 10.1097/RLI.0000000000000698. View

12.

Absinta M, Vuolo L, Rao A, Nair G, Sati P, Cortese I . Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015; 85(1):18-28. PMC: 4501940. DOI: 10.1212/WNL.0000000000001587. View

13.

Gillen K, Mubarak M, Park C, Ponath G, Zhang S, Dimov A . QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions. Ann Clin Transl Neurol. 2021; 8(4):877-886. PMC: 8045922. DOI: 10.1002/acn3.51338. View

14.

Herranz E, Treaba C, Barletta V, Mehndiratta A, Ouellette R, Sloane J . Characterization of cortico-meningeal translocator protein expression in multiple sclerosis. Brain. 2024; 147(7):2566-2578. PMC: 11224595. DOI: 10.1093/brain/awae030. View

15.

Kolb H, Absinta M, Beck E, Ha S, Song Y, Norato G . 7T MRI Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions. Ann Neurol. 2021; 90(4):612-626. PMC: 9291186. DOI: 10.1002/ana.26194. View

16.

Sati P . Diagnosis of multiple sclerosis through the lens of ultra-high-field MRI. J Magn Reson. 2018; 291:101-109. PMC: 6022748. DOI: 10.1016/j.jmr.2018.01.022. View

17.

Chomyk A, Kucinski R, Kim J, Christie E, Cyncynatus K, Gossman Z . Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis. Ann Neurol. 2024; 95(5):907-916. PMC: 11060930. DOI: 10.1002/ana.26877. View

18.

Fox R, Raska P, Barro C, Karafa M, Konig V, Bermel R . Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. Mult Scler. 2021; 27(13):2014-2022. PMC: 8387506. DOI: 10.1177/1352458520986956. View

19.

Absinta M, Sati P, Schindler M, Leibovitch E, Ohayon J, Wu T . Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest. 2016; 126(7):2597-609. PMC: 4922708. DOI: 10.1172/JCI86198. View

20.

Polvinen E, Matilainen M, Nylund M, Sucksdorff M, Airas L . TSPO-Detectable Chronic Active Lesions Predict Disease Progression in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023; 10(5). PMC: 10291892. DOI: 10.1212/NXI.0000000000200133. View